Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) Zheng Quan Zhi Xing·2025-08-21 22:32Financial Performance - The company reported a total revenue of 1.048 billion yuan for the first half of 2025, representing a year-on-year increase of 26.07% [1] - The net profit attributable to shareholders reached 310 million yuan, up 36.49% year-on-year [1] - The gross margin improved to 69.57%, an increase of 3.35% compared to the previous year, while the net margin rose to 28.84%, up 3.48% [1] Quarterly Analysis - In Q2 2025, the total revenue was 483 million yuan, showing a slight increase of 1.47% year-on-year [1] - The net profit for Q2 was 157 million yuan, which marked a decline of 2.12% year-on-year [1] Key Financial Ratios - The company’s total expenses (selling, administrative, and financial) amounted to 240 million yuan, accounting for 22.93% of revenue, an increase of 15.93% year-on-year [1] - Earnings per share (EPS) increased to 0.99 yuan, reflecting a growth of 30.26% year-on-year [1] Asset and Liability Changes - Cash and cash equivalents increased by 21.88% to 677 million yuan, primarily due to the redemption of structured deposits [3] - Interest-bearing liabilities surged by 72.94% to 2.026 billion yuan, indicating a significant increase in debt [1][3] - Accounts receivable rose by 25.75% to 613 million yuan, attributed to increased sales revenue [3] Investment and Development - The company has seen a 78.5% increase in construction in progress, driven by multiple ongoing projects [3] - The intangible assets grew by 42.39% due to the capitalization of certain pharmaceutical products [5] Cash Flow Analysis - The net cash flow from operating activities increased by 59.33%, attributed to higher cash collections from customers [26] - The net cash flow from investing activities decreased by 8.52%, reflecting increased purchases of fixed assets [26] Market Position and Business Model - The company’s return on invested capital (ROIC) was reported at 11.52%, indicating average capital returns [28] - The business model relies heavily on capital expenditures, necessitating careful evaluation of the profitability of these investments [28] Fund Holdings - The largest fund holding in the company is the "招商蓝筹精选股票A," which has increased its position, currently holding 2.7458 million shares [28]